Pegvisomant-primed GH stimulation test

Giorgio Radetti, Zida Wu, Heba H. Elsedfy, Mohamed El Kholy, Mauro Bozzola, Christian J. Strasburger

Research output: Contribution to journalArticle

Abstract

Objective: Provocative stimulation tests for GH assessment have poor reproducibility and can often elicit false positive results in normal children. The aim of our study was to evaluate the capability of pegvisomant, as an enhancer of GH secretion, in unmasking false-positive results in short children undergoing GH testing. Design: A prospective study was conducted between March 2005 and April 2006. Patients: Twenty-one short children (8 males and 13 females), aged 1.0-14.5 years, with a height of <2 SD scores below the mean were included in the study. Methods: All subjects underwent an l-DOPA stimulation test with evaluation of GH. At the end of the test, 1 mg/kg of pegvisomant was given subcutaneously and 3 days later an l-DOPA stimulation test was repeated. Results: There was a significant decrease of IGF-I SDS following pegvisomant (-1.75 ± 0.24 vs. -2.65 ± 0.23; P <0.0001) and a significant increase of the GH-peak (6.2 ± 0.91 vs. 15.3 ± 2.30 μg/l; P <0.0001). Among the 21 patients examined, 18 (85.7%) had an insufficient response (<10 μg/l) at the first stimulation. Ten of them (55.5%) showed normal secretion after priming with pegvisomant, while insufficient secretory reserve was confirmed in the remaining eight. Conclusions: Pegvisomant priming before GH stimulation tests can be used to improve the reliability of the diagnostic work up in GH deficiency. Further studies are required, however, to clarify whether this procedure should be recommended in the routine evaluation of GH status.

Original languageEnglish
Pages (from-to)951-956
Number of pages6
JournalClinical Endocrinology
Volume68
Issue number6
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Insulin-Like Growth Factor I
pegvisomant
Prospective Studies

ASJC Scopus subject areas

  • Endocrinology

Cite this

Radetti, G., Wu, Z., Elsedfy, H. H., El Kholy, M., Bozzola, M., & Strasburger, C. J. (2008). Pegvisomant-primed GH stimulation test. Clinical Endocrinology, 68(6), 951-956. https://doi.org/10.1111/j.1365-2265.2007.03132.x

Pegvisomant-primed GH stimulation test. / Radetti, Giorgio; Wu, Zida; Elsedfy, Heba H.; El Kholy, Mohamed; Bozzola, Mauro; Strasburger, Christian J.

In: Clinical Endocrinology, Vol. 68, No. 6, 06.2008, p. 951-956.

Research output: Contribution to journalArticle

Radetti, G, Wu, Z, Elsedfy, HH, El Kholy, M, Bozzola, M & Strasburger, CJ 2008, 'Pegvisomant-primed GH stimulation test', Clinical Endocrinology, vol. 68, no. 6, pp. 951-956. https://doi.org/10.1111/j.1365-2265.2007.03132.x
Radetti G, Wu Z, Elsedfy HH, El Kholy M, Bozzola M, Strasburger CJ. Pegvisomant-primed GH stimulation test. Clinical Endocrinology. 2008 Jun;68(6):951-956. https://doi.org/10.1111/j.1365-2265.2007.03132.x
Radetti, Giorgio ; Wu, Zida ; Elsedfy, Heba H. ; El Kholy, Mohamed ; Bozzola, Mauro ; Strasburger, Christian J. / Pegvisomant-primed GH stimulation test. In: Clinical Endocrinology. 2008 ; Vol. 68, No. 6. pp. 951-956.
@article{5fcb09a8199049fd9bd17642f95f967f,
title = "Pegvisomant-primed GH stimulation test",
abstract = "Objective: Provocative stimulation tests for GH assessment have poor reproducibility and can often elicit false positive results in normal children. The aim of our study was to evaluate the capability of pegvisomant, as an enhancer of GH secretion, in unmasking false-positive results in short children undergoing GH testing. Design: A prospective study was conducted between March 2005 and April 2006. Patients: Twenty-one short children (8 males and 13 females), aged 1.0-14.5 years, with a height of <2 SD scores below the mean were included in the study. Methods: All subjects underwent an l-DOPA stimulation test with evaluation of GH. At the end of the test, 1 mg/kg of pegvisomant was given subcutaneously and 3 days later an l-DOPA stimulation test was repeated. Results: There was a significant decrease of IGF-I SDS following pegvisomant (-1.75 ± 0.24 vs. -2.65 ± 0.23; P <0.0001) and a significant increase of the GH-peak (6.2 ± 0.91 vs. 15.3 ± 2.30 μg/l; P <0.0001). Among the 21 patients examined, 18 (85.7{\%}) had an insufficient response (<10 μg/l) at the first stimulation. Ten of them (55.5{\%}) showed normal secretion after priming with pegvisomant, while insufficient secretory reserve was confirmed in the remaining eight. Conclusions: Pegvisomant priming before GH stimulation tests can be used to improve the reliability of the diagnostic work up in GH deficiency. Further studies are required, however, to clarify whether this procedure should be recommended in the routine evaluation of GH status.",
author = "Giorgio Radetti and Zida Wu and Elsedfy, {Heba H.} and {El Kholy}, Mohamed and Mauro Bozzola and Strasburger, {Christian J.}",
year = "2008",
month = "6",
doi = "10.1111/j.1365-2265.2007.03132.x",
language = "English",
volume = "68",
pages = "951--956",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Pegvisomant-primed GH stimulation test

AU - Radetti, Giorgio

AU - Wu, Zida

AU - Elsedfy, Heba H.

AU - El Kholy, Mohamed

AU - Bozzola, Mauro

AU - Strasburger, Christian J.

PY - 2008/6

Y1 - 2008/6

N2 - Objective: Provocative stimulation tests for GH assessment have poor reproducibility and can often elicit false positive results in normal children. The aim of our study was to evaluate the capability of pegvisomant, as an enhancer of GH secretion, in unmasking false-positive results in short children undergoing GH testing. Design: A prospective study was conducted between March 2005 and April 2006. Patients: Twenty-one short children (8 males and 13 females), aged 1.0-14.5 years, with a height of <2 SD scores below the mean were included in the study. Methods: All subjects underwent an l-DOPA stimulation test with evaluation of GH. At the end of the test, 1 mg/kg of pegvisomant was given subcutaneously and 3 days later an l-DOPA stimulation test was repeated. Results: There was a significant decrease of IGF-I SDS following pegvisomant (-1.75 ± 0.24 vs. -2.65 ± 0.23; P <0.0001) and a significant increase of the GH-peak (6.2 ± 0.91 vs. 15.3 ± 2.30 μg/l; P <0.0001). Among the 21 patients examined, 18 (85.7%) had an insufficient response (<10 μg/l) at the first stimulation. Ten of them (55.5%) showed normal secretion after priming with pegvisomant, while insufficient secretory reserve was confirmed in the remaining eight. Conclusions: Pegvisomant priming before GH stimulation tests can be used to improve the reliability of the diagnostic work up in GH deficiency. Further studies are required, however, to clarify whether this procedure should be recommended in the routine evaluation of GH status.

AB - Objective: Provocative stimulation tests for GH assessment have poor reproducibility and can often elicit false positive results in normal children. The aim of our study was to evaluate the capability of pegvisomant, as an enhancer of GH secretion, in unmasking false-positive results in short children undergoing GH testing. Design: A prospective study was conducted between March 2005 and April 2006. Patients: Twenty-one short children (8 males and 13 females), aged 1.0-14.5 years, with a height of <2 SD scores below the mean were included in the study. Methods: All subjects underwent an l-DOPA stimulation test with evaluation of GH. At the end of the test, 1 mg/kg of pegvisomant was given subcutaneously and 3 days later an l-DOPA stimulation test was repeated. Results: There was a significant decrease of IGF-I SDS following pegvisomant (-1.75 ± 0.24 vs. -2.65 ± 0.23; P <0.0001) and a significant increase of the GH-peak (6.2 ± 0.91 vs. 15.3 ± 2.30 μg/l; P <0.0001). Among the 21 patients examined, 18 (85.7%) had an insufficient response (<10 μg/l) at the first stimulation. Ten of them (55.5%) showed normal secretion after priming with pegvisomant, while insufficient secretory reserve was confirmed in the remaining eight. Conclusions: Pegvisomant priming before GH stimulation tests can be used to improve the reliability of the diagnostic work up in GH deficiency. Further studies are required, however, to clarify whether this procedure should be recommended in the routine evaluation of GH status.

UR - http://www.scopus.com/inward/record.url?scp=43949126891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43949126891&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2007.03132.x

DO - 10.1111/j.1365-2265.2007.03132.x

M3 - Article

C2 - 18031320

AN - SCOPUS:43949126891

VL - 68

SP - 951

EP - 956

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -